Modern concept of a new group of retinal vasculitis
https://doi.org/10.21516/2072-0076-2021-14-4-149-153
Abstract
Retinal vasculitis is a rare condition that occurs both in systemic severe diseases and as an adverse event of intraocular drug injections. With the emergence of new anti-VEGF drugs, a number of international authors report on the occurrence of retinal occlusive vasculitis, which led to a decrease in visual acuity. The review presents possible pathogeneses of this condition, approaches to its diagnosis and an algorithm for managing the patients with occlusive vasculitis.
About the Authors
I. A. Loskutov
Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
Igor A. Loskutov — Dr. of Med. Sci., head of ophthalmological department
61/2, Schepkina St., Moscow, 129110
A. A. Kovrizhkina
Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
Alina A. Kovrizhkina — researcher, ophthalmological department
61/2, Schepkina St., Moscow, 129110
O. M. Andryuhina
Moscow Regional Research and Clinical Institute (MONIKI)
Russian Federation
Russian Federation
Olga M. Andryuhina — Cand. of Med. Sci., senior researcher, ophthalmological department
61/2, Schepkina St., Moscow, 129110
References
1. Ku J.H., Ali A., Suhler E.B., Choi D., Rosenbaum J.T. Characteristics and visual outcome of patients with retinal vasculitis. Arch. Ophthalmol. 2012; 130 (10): 1261–6. doi: 10.1001/archophthalmol.2012.1596
2. Herbort C.P., Cimino L., Abu E.L., Asrar A.M. Ocular vasculitis: a multidisciplinary approach. Curr. Opin. Rheumatol. 2005; 17 (1): 25–33. doi: 10.1097/01.bor.0000149083.16639.7e
3. Brydak-Godowska J., Dróbecka-Brydak E. [Retinal vasculitis — causes, diagnosis, treatment]. Klin. Oczna. 2007; 109 (1–3): 71–3.
4. Donaldson L., Margolin E. Vision loss in giant cell arteritis. Pract. Neurol. 2021 Jul 8. Available at: http://dx.doi.org/10.1136/practneurol-2021-002972.
5. Yang Shizhao, Huang Zhaohao, Hu Yunwei, et al. The efficacy of adalimumab as an initial treatment in patients with Behçet's retinal vasculitis. Frontiers in pharmacology. 2021; 12: 609148. doi:10.3389/fphar.2021.609148
6. Russo R., Katsicas M. Takayasu Arteritis. Frontiers in pediatrics. 2018; 6: 265. doi: 10.3389/fped.2018.00265
7. Chun Y.S., Park S.J., Park I.K., Chung H., Lee J. The clinical and ocular manifestations of Takayasu arteritis. Retina. 2001; 21 (2): 132–40. doi: 10.1097/00006982-200104000-00006
8. Ustinova E.I. Classification of endogenous uveitis. Oftal'mologicheskie vedomosti. 2016; 9 (2): 74–80 (in Russian).
9. Baranov A.A. Systemic vasculitis: modern standards for diagnosis and treatment. Russkij meditsinskij zhurnal. 2005; 24: 1577 (in Russian).
10. Hughes E.H, Dick A.D. The pathology and pathogenesis of retinal vasculitis. Neuropathol. Appl. Neurobiol. 2003; 29 (4): 325–40. doi: 10.1046/j.1365-2990.2003.00499.x
11. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am. J. Ophthalmol. 2005; 140 (3): 509–16. doi: 10.1016/j.ajo.2005.03.057
12. Prete M., Indiveri F., Perosa F. Vasculitides: Proposal for an integrated nomenclature. Autoimmun Rev. 2016; 15 (2): 167–73. doi: 10.1016/j.autrev.2015.10.008
13. Datoo O'Keefe G.A., Rao N. Retinal vasculitis: A framework and proposal for a classification system. Surv Ophthalmol. 2021; 66 (1): 54–67. doi: 10.1016/j.survophthal.2020.05.004
14. Witkin A.J., Chang D.F., Jumper J.M., et al. Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes. Ophthalmology. 2017; 124 (5): 583–95. doi: 10.1016/j.ophtha.2016.11.042
15. Muid J., Awan M.A. Haemorrhagic occlusive retinal vasculitis caused by intravitreal vancomycin. J. Pak. Med. Assoc. 2020; 70 (9): 1648–50. doi: 10.5455/JPMA.46528
16. El Gendy H.A. Vancomycin-associated retinal hemorrhages in pediatric age group: A case report. Am. J. Ophthalmol. Case Rep. 2020; 20: 100880. doi: 10.1016/j.ajoc.2020.100880
17. Witkin A.J., Shah A.R., Engstrom R.E., et al. Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin. Ophthalmology. 2015; 122 (7): 1438–51. doi: 10.1016/j.ophtha.2015.03.016
18. Jiao B., You E., Chemali K., et al. Ocular inflammatory and retinal vascular occlusive adverse events of intravitreal anti-VEGF injections: A systematic review and network meta-analysis. Invest. Ophthalmol. Vis. Sci. 2021; 62: 453. https://iovs.arvojournals.org/article.aspx?articleid=2772806
19. Von Hanno T., Kinge B., Fossen K. Retinal artery occlusion following intravitreal anti VEGF therapy. Acta ophthalmologica. 2010; 88 (2): 263–6. doi: 10.1111/j.1755-3768.2008.01406.x
20. Witkin A.J., Hahn P., Murray T.G., et al. Occlusive retinal vasculitis following intravitreal brolucizumab. J. Vitreoretin Dis. 2020; 4 (4): 269–79. doi:10.1177/2474126420930863
21. Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am. J. Ophthalmol. Case Rep. 2020; 18: 100687. doi: 10.1016/j.ajoc.2020.100687
22. Antaki F., Vadboncoeur J. Retinal vasculitis after intravitreal injection of brolucizumab. Can. J. Ophthalmol. 2021 May 7:S0008-4182(21)00133-2. doi: 10.1016/j.jcjo.2021.04.004
23. Leclaire M.D., Lauermann J., Alten F., Eter N. Intraokuläre Entzündung mit okklusiver retinaler Vaskulitis nach intravitrealer Brolucizumab-Injektion [Intraocular inflammation with occlusive retinal vasculitis following intravitreal injection of brolucizumab]. Ophthalmologe. 2021 Feb 24. German. doi: 10.1007/s00347-021-01341-4
24. Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi: 10.1007/s00347-021-01321-8
25. Hikichi T. Three Japanese cases of intraocular inflammation after intravitreal brolucizumab injections in one clinic. Jpn. J. Ophthalmol. 2021; 65 (2): 208–14. doi: 10.1007/s10384-021-00819-7
26. Iyer P.G., Peden M.C., Suñer I.J., et al. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: a clinicopathologic case study. Am. J. Ophthalmol. Case Rep. 2020; 20: 100989. doi:10.1016/j.ajoc.2020.100989
27. Sharma A., Kumar N., Parachuri N., et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam's Razor? Ocul. Immunol. Inflamm. 2021; May 20: 1–3. doi: 10.1080/09273948.2021.1897628
28. Jain A., Chea S., Matsumiya W., et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. American Journal of Ophthalmology Case Reports. 2020; 18: 100687. doi:10.1016/j.ajoc.2020.100687
29. Monés J., Srivastava S.K., Jaffe G.J., et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with brolucizumab: post hoc review of HAWK and HARRIER. Ophthalmology. 2021; 128 (7): 1050–9. doi: 10.1016/j.ophtha.2020.11.011
30. Baumal C.R., Spaide R.F., Vajzovic L., et al. Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020; 127 (10): 1345–59. doi: 10.1016/j.ophtha.2020.04.017
31. Zornikov D.L., Litusov N.V., Novoselov A.V. Immunopathology. Ekaterinburg: UGMU; 2017 (in Russian).
32. Mauldin E.A., Peters-Kennedy J. Integumentary System. Jubb, Kennedy & Palmer's Pathology of Domestic Animals: Volume 1. 2016; 509–736.e1. doi:10.1016/B978-0-7020-5317-7.00006-0
33. Hsu Y.O., Lu K.L., Fu Y., et al. The roles of immunoregulatory networks in severe drug hypersensitivity. Frontiers in immunology. 2021; 12: 597761. https://doi.org/10.3389/fimmu.2021.597761
34. Haug S.J., Hien D.L., Uludag G., et al. Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. American journal of ophthalmology case reports. 2020; 18: 100680. https://doi.org/10.1016/j.ajoc.2020.100680
35. Holz F.G., Heinz C., Wolf A., Hoerauf H., Pleyer U. [Intraocular inflammation with brolucizumab use: Patient management-diagnosis-therapy]. Ophthalmologe. 2021; 118 (3): 248–56. doi:10.1007/s00347-021-01321-8
36. Assessment report Beovu International non-proprietary name: brolucizumab Procedure No. EMEA/H/C/004913/0000. 12 December 2019 EMA/23630/2020 Committee for Medicinal Products for Human Use (CHMP) Available at: https://www.ema.europa.eu/en/documents/assessment-report/beovu-epar-public-assessment-report_en.pdf
37. Novartis. Safety of Beovu®(brolucizumab). Available at: https://www.brolucizumab.info
38. Kunimoto D., Yoon Y.H., Wykoff C.C., et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020; 127: 10: 1331-44. doi: 10.1016/j.ophtha.2020.03.035
39. Hussain R.M., Weng C.Y., Wykoff C.C., Gandhi R.A., Hariprasad S.M. Abicipar pegol for neovascular age-related macular degeneration. Expert opinion on biological therapy. 2020; 20 (9): 999–1008. doi: 10.1080/14712598.2020.1782379
40. Information letter dated 08/18/2021 No. 02I-1035/21. About new safety data of the drug Beovue® ( brolucizumab) (In Russian) Available at: https://roszdravnadzor.gov.ru/documents/74091
41. Witkin A. J., Hahn P., Murray T.G., et al. Research and Safety in Therapeutics Committee, American Society of Retina Specialists. Brolucizumab-associated intraocular inflammation in eyes without retinal vasculitis. Journal of VitreoRetinal Diseases, 2021; 5 (4): 326–32. doi: 10.1177/2474126420975303
42. Baumal C.R., Bodaghi B., Singe M., et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmology Retina. 2021; 5 (6): 519–27. doi:10.1016/j.oret.2020.09.020
43. Sharma A., Kumar N., Parachuri N., et al. Brolucizumab — foreseeable workflow in the current scenario. Eye. 2021; 35(6): 1548-50. doi: 10.1038/s41433-020-01324-w
44. Nesrine A., Sourour Z., Molka K., et al. Diagnosing retinal vasculitis and its implications for treatment. Expert Review of Ophthalmology. 2019; 14 (3): 151–67. https://doi.org/10.1080/17469899.2019.1613153
45. Wang P., Chin E.K., Almeida D.R. Idiopathic retinal arterial occlusive vasculitis in the setting of multiple arterial occlusions. Am. J. Ophthalmol. Case Rep. 2021; 22: 101086. doi:10.1016/j.ajoc.2021.101086
Review
For citations:
Loskutov I.A., Kovrizhkina A.A., Andryuhina O.M. Modern concept of a new group of retinal vasculitis. Russian Ophthalmological Journal. 2021;14(4):149-153. (In Russ.) https://doi.org/10.21516/2072-0076-2021-14-4-149-153
Views:
1005
Email this article 